

Qualification details not available
Corporate
Private Equity
Mergers and Acquisitions
Foreign Direct Investments
Jack Sun is a Legal Manager at Paul, Weiss, based in the firm's Hong Kong office. He specializes in China-related private equity investments, cross-border mergers and acquisitions, and foreign direct investments. Jack holds an LL.B. from Peking University Law School and is fluent in both English and Mandarin. His expertise in corporate law and his focus on international transactions make him a valuable asset to the firm's Corporate Department.
Mergers & Acquisitions
Capital Markets

- Qualcomm Incorporated acquired the target/assets from Alphawave IP Group plc in a acquisition on not available. - Deal value was 2400000000 Sector: Technology; Location: UK. - On the acquirer side, not available advised, led by Brian Krause, Brianna van Kan, Cian O'Connor, Dan Schuster-Woldan, Deeksha Rathi, Jeffrey Samuels, John Patten, Jonathan Ashtor, Judie Ng Shortell, Kyle Seifried, Matthew Friestedt, Matthew Hearn, Nicole Kar, Patricia Vaz de Almeida, Scott Barshay, Scott Sher.
Jun 09 2025
2B
M&A

Legal Manager
Unknown


- GSK plc acquired the target/assets from Chimagen Biosciences in a acquisition on 2024-10-29. - Deal value was 3000000000 (source: Extracted) Ownership: full global rights; Sector: Biotechnology; Location: UK. - On the acquirer side, Paul, Weiss advised, led by Krishna Veeraraghavan, Benjamin Goodchild, Jonathan Ashtor, Bonnie Chen.
Oct 29 2024
850M
M&A

Paul, Weiss is advising UK-based GSK plc in its proposed acquisition of an investigational molecule used to treat autoimmune disease from Chimagen Biosciences, a China-based privately held biotechnology company. Under the terms of the agreement, GSK will pay $300 million up front to acquire the full global rights to the molecule, CMG1A46. Chimagen will also be eligible to receive success-based development and commercial milestone payments for CMG1A46 totaling $550 million. GSK plans to develop and commercialize CMG1A46, with a focus on certain types of lupus, with potential to expand into related autoimmune diseases. The transaction is subject to customary closing conditions and regulatory approvals. The Paul, Weiss team is led by partners Krishna Veeraraghavan, Benjamin Goodchild, Jonathan Ashtor and Bonnie Chen, and includes corporate partner Judie Ng Shortell and counsel Jack Sun; tax partner Cian O’Connor; and litigation partners Geoffrey Chepiga and Crystal Parker.
Oct 29

1 min